Eisai (TYO:4523) and Biogen plan to begin producing active ingredients for their Alzheimer's drug lecanemab in the US, shifting part of the work from Switzerland, Nikkei Asia Review reported Thursday.
The move came amid concern that US President Donald Trump would impose tariffs on pharmaceutical imports, the report said.
Biogen, which manufactures the drug, is preparing to build an ingredient production line at the North Carolina site, with the aim to begin domestic production within one to two years, the report said.
Eisai described the decision as part of its cost-cutting efforts but acknowledged the change would also help hedge against potential US tariffs, Nikkei reported.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。